BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32212266)

  • 1. PTPN11 mutations in canine and human disseminated histiocytic sarcoma.
    Hédan B; Rault M; Abadie J; Ulvé R; Botherel N; Devauchelle P; Copie-Bergman C; Cadieu E; Parrens M; Alten J; Zalcman EL; Cario G; Damaj G; Mokhtari K; Le Loarer F; Coulomb-Lhermine A; Derrien T; Hitte C; Bachelot L; Breen M; Gilot D; Blay JY; Donadieu J; André C
    Int J Cancer; 2020 Sep; 147(6):1657-1665. PubMed ID: 32212266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating Mutations in
    Takada M; Smyth LA; Thaiwong T; Richter M; Corner SM; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
    Genes (Basel); 2019 Jul; 10(7):. PubMed ID: 31277422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs.
    Thaiwong T; Sirivisoot S; Takada M; Yuzbasiyan-Gurkan V; Kiupel M
    Vet Comp Oncol; 2018 Jun; 16(2):220-228. PubMed ID: 28929581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting MEK in a Translational Model of Histiocytic Sarcoma.
    Takada M; Hix JML; Corner S; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
    Mol Cancer Ther; 2018 Nov; 17(11):2439-2450. PubMed ID: 30135215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA is detectable in canine histiocytic sarcoma, oral malignant melanoma, and multicentric lymphoma.
    Prouteau A; Denis JA; De Fornel P; Cadieu E; Derrien T; Kergal C; Botherel N; Ulvé R; Rault M; Bouzidi A; François R; Dorso L; Lespagnol A; Devauchelle P; Abadie J; André C; Hédan B
    Sci Rep; 2021 Jan; 11(1):877. PubMed ID: 33441840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
    Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
    Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
    Asada H; Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
    J Vet Med Sci; 2015 Jun; 77(6):677-84. PubMed ID: 25715778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma.
    Tani H; Miyamoto R; Nagashima T; Michishita M; Tamura K; Bonkobara M
    Vet Comp Oncol; 2022 Mar; 20(1):109-117. PubMed ID: 34241941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
    Shanmugam V; Griffin GK; Jacobsen ED; Fletcher CDM; Sholl LM; Hornick JL
    Mod Pathol; 2019 Jun; 32(6):830-843. PubMed ID: 30626916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology, pathology, and genetics of histiocytic sarcoma in the Bernese mountain dog breed.
    Abadie J; Hédan B; Cadieu E; De Brito C; Devauchelle P; Bourgain C; Parker HG; Vaysse A; Margaritte-Jeannin P; Galibert F; Ostrander EA; André C
    J Hered; 2009; 100 Suppl 1():S19-27. PubMed ID: 19531730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior.
    Hedan B; Thomas R; Motsinger-Reif A; Abadie J; Andre C; Cullen J; Breen M
    BMC Cancer; 2011 May; 11():201. PubMed ID: 21615919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma.
    Lenz JA; Assenmacher CA; Costa V; Louka K; Rau S; Keuler NS; Zhang PJ; Maki RG; Durham AC; Radaelli E; Atherton MJ
    Cancer Immunol Immunother; 2022 Apr; 71(4):807-818. PubMed ID: 34415404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intratumor heterogeneity of TP53 gene mutations in canine histiocytic sarcoma.
    Asada H; Ichii O; Tomiyasu H; Uchida K; Chambers JK; Goto-Koshino Y; Ohno K; Kon Y; Tsujimoto H
    J Vet Med Sci; 2019 Mar; 81(3):353-356. PubMed ID: 30662044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of common predisposing loci to hematopoietic cancers in four dog breeds.
    Hédan B; Cadieu É; Rimbault M; Vaysse A; Dufaure de Citres C; Devauchelle P; Botherel N; Abadie J; Quignon P; Derrien T; André C
    PLoS Genet; 2021 Apr; 17(4):e1009395. PubMed ID: 33793571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 2-base insertion in exon 5 is a common mutation of the TP53 gene in dogs with histiocytic sarcoma.
    Asada H; Tsuboi M; Chambers JK; Uchida K; Tomiyasu H; Goto-Koshino Y; Ohno K; Tsujimoto H
    J Vet Med Sci; 2017 Oct; 79(10):1721-1726. PubMed ID: 28867679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
    Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
    Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical prognostic factors in canine histiocytic sarcoma.
    Dervisis NG; Kiupel M; Qin Q; Cesario L
    Vet Comp Oncol; 2017 Dec; 15(4):1171-1180. PubMed ID: 27334037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and characterisation of cell lines and xenograft mouse models of canine systemic histiocytosis and disseminated histiocytic sarcoma.
    Hirabayashi M; Chambers JK; Kishimoto TE; Nguyen SV; Ishikawa Y; Rimpo K; Nakayama H; Uchida K
    Vet Comp Oncol; 2022 Jun; 20(2):465-475. PubMed ID: 34907644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
    Cronise KE; Hernandez BG; Gustafson DL; Duval DL
    Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of the two-base insertion mutation in the TP53 gene in canine histiocytic sarcoma.
    Asada H; Tomiyasu H; Okada K; Chambers JK; Goto-Koshino Y; Uchida K; Kagawa Y; Ohno K; Tsujimoto H
    Res Vet Sci; 2019 Jun; 124():57-60. PubMed ID: 30852355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.